Taken together, our results show that PLK1 activity is essential to inducing tumor formation and metastasis and that it can effectively be blocked by the specific inhibitor volasertib in an animal model, as well as in cell-based experiments, suggesting that PLK1 is an effective target for treating cancer metastasis. Here, PLK1 is linked to neoplasm.